An unprecedented surge in AI-driven demand for computer memory has created a global shortage and sent prices skyrocketing. This situation creates a powerful tailwind for memory chip manufacturers who are pivotal to the AI supply chain.
Published on January 12
AI's explosive growth has created an unprecedented shortage of memory chips, driving prices higher and creating sustained profit opportunities for manufacturers.
These companies control critical parts of the memory supply chain, from chip design to manufacturing equipment, giving them pricing power in a supply-constrained market.
Professional analysts identified these firms as best positioned to capitalise on the shift toward premium, high-margin memory components essential for AI expansion.
The explosive growth of artificial intelligence has created an unprecedented demand for specialised memory chips like DRAM and HBM. This surge has far outpaced global supply capacity, creating a powerful market imbalance that's driving prices higher and generating significant opportunities for companies in the memory supply chain.
This shortage isn't temporary - AI applications require vast amounts of high-performance memory, and current production can't keep up. The resulting price inflation affects everything from data centres to consumer devices, creating a sustained tailwind for memory manufacturers and their suppliers across the semiconductor ecosystem.
These companies were handpicked by professional analysts for their strategic positions in the memory value chain. From chip designers and manufacturers to equipment providers and testing services, each plays a crucial role in addressing the supply-demand imbalance and stands to benefit from sustained high prices and increased profitability.
This basket's total market capitalisation is $2.65T and is strongly anchored by a few very large-cap holdings, concentrating most of the weight in established companies.
MU: $388.40B
TSM: $1.38T
INTC: $217.27B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
If you invested across these assets:
In 12 months it might be worth:
+13.85%
On average, analysts expect assets in this group to grow 13.85% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
